Delivery Order SPE2DB22D9143-SPE2DB23FZB59

This is a $5,762.72 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the provision of XOLAIR 150 MG/ML SYRINGEML, a medical product, with a period of performance through July 3, 2025. This award is not set aside and is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves to provide a...

The Defense Logistics Agency awarded a $773 firm fixed price delivery order to DMS Pharmaceutical Group Inc. of Park Ridge, Illinois. The order is for 4562235601 XOLAIR 150 MG/ML SYRINGEML, to be delivered by October 5, 2023. Xolair is the brand name for omalizumab, a prescription medicine that reduces the amount of antibody IgE in the blood. This delivery order was issued under an existing DLA pharmaceutical supply contract vehicle, with no set-aside designation specified. DMS Pharmaceutical...

The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc. a $386 firm fixed price delivery order for XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML. The order was awarded on October 4, 2023 under an unspecified contract vehicle and has a period of performance concluding on October 26, 2023. To be delivered to Park Ridge, Illinois, the syringes will support DLA's mission to provide pharmaceuticals and other medical supplies to the U.S. military and other government agencies. No set-aside provision...

The Defense Logistics Agency awarded a $9,813 firm fixed price delivery order to DMS Pharmaceutical Group Inc. to supply 4558369217 XOLAIR 150 MG/ML SYRINGEML. The contract has a period of performance from September 1, 2022 through September 23, 2022 and will be performed in Park Ridge, Illinois. The delivery order was issued against an existing DLA pharmaceuticals contract vehicle to provide the specified medication in support of DoD health programs. No set aside designation or subcontractors...

The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate to severe allergic asthma and other allergic...

This delivery order for $23,211 was awarded by the Defense Logistics Agency to DMS Pharmaceutical Group Inc. of Park Ridge, Illinois. The order is for 4562584463 units of XOLAIR 150 MG/ML SYRINGES with a completion date of November 13, 2023. XOLAIR is used to treat allergic asthma and chronic idiopathic urticaria. No set-aside designation was used for this firm fixed price order to supply the pharmaceutical to the Defense Logistics Agency, the agency within the Department of Defense that...

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XOLAIR 150 MG/ML SYRINGE, a pharmaceutical product, with a ceiling value of $2,161.02 and a period of performance through July 29, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract...

This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XOLAIR 150 MG/ML SYRINGE, a pharmaceutical product, with a ceiling value of $8,644.08 and a period of performance through July 30, 2025. The contract is a firm fixed-price delivery order, indicating the government is purchasing a specific quantity of the product at a set...

This delivery order, awarded by the Defense Logistics Agency to DMS Pharmaceutical Group Inc., is for $9,284.40 to supply 4560792429 units of XOLAIR 150 MG/1.2 ML powder for injection. The place of performance is Park Ridge, Illinois and all work must be completed by May 19, 2023. No set-aside provisions were applied to this firm fixed price award. As the Defense Logistics Agency is responsible for worldwide logistics support of the Department of Defense, this order is likely providing an...

The Defense Logistics Agency awarded a $2,881.36 delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes on August 13, 2025, with completion scheduled for September 4, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, making...